At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRX Immuneering Corp
Not Yet Opened 11-21 16:00:00 EST
2.11
+0.07
+3.43%
盘后2.10
-0.01-0.39%
19:58 EST
High2.23
Low2.03
Vol478.92K
Open2.03
D1 Closing2.04
Amplitude9.80%
Mkt Cap62.57M
Tradable Cap44.30M
Total Shares29.65M
T/O1.02M
T/O Rate2.28%
Tradable Shares20.99M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Cautious Hold Recommendation on Immuneering Amid Promising Developments and Financial Uncertainties
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.